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Abstract People with Down’s syndrome (DS) are at high
risk for developing Alzheimer’s disease (AD) at a rela-
tively young age. This increased risk is not observed in
people with intellectual disabilities for reasons other than
DS and for this reason it is unlikely to be due to non-
specific effects of having a neurodevelopmental disorder
but, instead, a direct consequence of the genetics of DS
(trisomy 21). Given the location of the amyloid precursor
protein (APP) gene on chromosome 21, the amyloid cas-
cade hypothesis is the dominant theory accounting for this
risk, with other genetic and environmental factors modi-
fying the age of onset and the course of the disease. Several
potential therapies targeting the amyloid pathway and
aiming to modify the course of AD are currently being
investigated, which may also be useful for treating AD in
DS. However, given that the neuropathology associated
with AD starts many years before dementia manifests, any
preventative treatment must start well before the onset of
symptoms. To enable trials of such interventions, plasma,
CSF, brain, and retinal biomarkers are being studied as
proxy early diagnostic and outcome measures for AD. In
this systematic review, we consider the prospects for the
development of potential preventative treatments of AD in
the DS population and their evaluation.
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Background
Just over 20 years after the first description by Alzheimer
of the characteristic neuropathology of extracellular pla-
ques and intracellular neurofibrillary tangles associated
with ‘senile dementia’, the first report of a similar neu-
ropathology in people with DS was published [1]. Similar
findings from further neuropathological studies were sub-
sequently reported and later in the 20th century a number
of cross-sectional clinical studies found that with increas-
ing age many but not all people with DS were at risk for
cognitive and functional decline not obviously dissimilar to
that observed in the typically developing population with
Alzheimer’s disease (AD) [2]. Over this period, the mean
life expectancy for people with DS continued to improve
[3] reaching an average of 60 years [4]. Consequently there
has been an increase in the prevalence of age-related
morbidities such as dementia. The overall prevalence of
dementia in adults with DS is estimated at [1] 6.8 % with
an increase with age from 8.9 % in individuals up to
49 years to 32.1 % in individuals from 55 to 59 years old
[5]. However, the exact age-related percentages differ
between studies with some reporting prevalence rates of
50 % or more in people with DS in their 50 s [6–8] (see
Fig. 1) with other genetic and possible environmental
factors influencing risk [9–11].
More recent clinical studies have focussed on the early
characteristics and course of dementia in people with DS
[12, 13] and, given that the diagnosis of dementia may be
difficult in people with pre-existing intellectual disabilities,
efforts have also been made to improve the reliability of
diagnosis [14, 15]. When these various studies are con-
sidered together it is clear that there is a discrepancy, with
most neuropathological studies reporting that almost
100 % of people with DS over the age of 35 have the
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neuropathology of AD, whereas in contrast clinical studies
have found that not everyone with DS develops the clinical
symptoms of dementia with increasing age [16, 17]. Fur-
thermore, unlike the general population, memory loss is not
invariably the earliest reported clinical feature. Prior to
clinically diagnosed dementia or shortly after the clinical
features are apparent, myoclonic or generalised seizures
[18] may develop together with the onset of behavioural
changes, and deterioration in performance on executive
function tasks and working memory. Later in the course of
dementia, deterioration in language use and comprehension
and loss of functional abilities are characteristic of the
subsequent course of dementia in people with DS. The
mean age of onset of diagnosed AD in people with DS is
reported at around 54 years [19].
Building on these earlier clinical studies advances in
neuroimaging are now part of a new wave of research,
which has focussed on understanding the mechanisms that
underpin the relationship between a neurodevelopmental
disorder (DS), on the one hand, and an illness with its onset
in later life (AD), on the other. The aim of this review is to
consider the challenges and possibilities of developing
treatments to prevent AD in people with DS.
Methodology
A thorough search of the Cochrane Library was performed
to ensure that there were no other previous reviews pub-
lished on the exact same topic. The initial literature search
was performed on the PUBMED database using the key-
words Alzheimer’s disease OR dementia AND biomarkers
AND Down syndrome with limiters of full-text, English,
written over the last 10 years and journal articles. Sixty-
two articles were found and 31 were selected due to rele-
vance to the topic. The same keywords were used in a
MEDLINE database search in a different order (Down
syndrome AND Alzheimer’s disease OR dementia AND
biomarkers), which provided a result of 68 articles. Only
five (excluding duplicates) were related to this research
topic, and these were selected. Then, a different search was
performed in PUBMED using the keywords Alzheimer’s
disease AND treatment AND Down syndrome with the
limiters of journal articles, full text, written in the last
10 years and English. One hundred and eighty-four articles
were found, and 35 were selected (excluding the dupli-
cates). Again, using the same keywords in MEDLINE and
the limiters being linked full text, abstract available and
English language, the search provided 12 articles, and three
were selected (excluding duplicates). Based on the selected
articles, a search for more specific literature was performed
from their reference lists, gathering 33 articles from sec-
ondary sources. After excluding duplicates, screening the
articles to meet the criteria and excluding full-text articles
that did not relate to the topic of this literature review, in
total, the present study compiled 39 articles related to
possible preventative therapies for AD and 34 articles on
the biomarkers topic (see ‘‘Appendix’’).
AD pathogenesis in DS: the amyloid cascade
hypothesis
In the 1990s it was proposed that the depositions of b-
amyloid (Ab) protein and amyloid plaque formation in the
brain were the main causes of the subsequent additional
neuropathological hallmarks of AD, which are neurofib-
rillary tangles, vascular damage, an inflammatory response,
and neuronal cell death [20, 21]. This theory is still the
basis for much research and treatment developments in AD
[22]. The association between early onset AD and muta-
tions in the amyloid precursor protein (APP) and presenilin
genes [23] has been central to the promotion of the amyloid
cascade hypothesis. The observations in DS and the high
risk of early onset AD have also provided important sup-
port for this hypothesis, given that the gene for APP is
located on chromosome 21 [24] and therefore along with
other genes on chromosome 21 it is inherited in triplicate
by people with DS [25]. Much is now known about the
amyloid pathway with the subsequent cleavage of APP by
two enzymes b and c-secretase creating the soluble product
of Ab [26]. Other factors, both in the general population
and in people with DS, contribute to the extent of Ab
pathology, such as the status of the apolipoprotein E
(ApoE) genotype. When ApoE4 (e4) is present in DS, the
risk for AD is even higher, with a two-fold increase in the
amyloid load deposited in the brain [27, 28]. In contrast,
when e2 allele is present, it is associated with increased
longevity and the absence of dementia [29]. Neuro-in-
flammation is also known to play a role in the pathogenesis
Fig. 1 Age-specific prevalence of dementia in adults with Down’s
syndrome [9]. Line with filled diamond data from Lai and Williams
[6]; dot with triangle data from Visser et al. [7]; line with filled square
data from Lai et al. [11]; line with filled dot data from Holland et al.
[8]
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of AD, especially through microglia activation [30], and it
may be more influential in DS as genes regulating
inflammatory processes, such as mir-155 and the s100
calcium-binding protein beta (S100B), are located on
chromosome 21 [25]. These latter gene products are
thought to impact cognitive impairment and neurodegen-
eration [31], as it has been proposed that inflammatory
processes accelerate the development of AD in DS [32].
The development of treatments
Pharmacological approaches to the treatment of AD in
people with DS have been based largely on the cholinergic
hypothesis of AD and the use of anticholinesterase inhi-
bitors. In DS these early pharmacological treatments were
found to ameliorate to a limited extent the symptoms of
AD, but did not affect its subsequent course [33]. In the
general population, in addition to pharmacological
approaches, attention has also focussed on aspects of life
style and modification of specific risk factors that may alter
the disease course. These have included: exercise [34],
blood pressure [35], obesity [36], diabetes [37], and the use
of statins [38]. These factors have not been assessed in
people with DS although, interestingly, there has been one
proof of concept trial of statins in people with DS that
showed a potential positive effect on age-related cognitive
decline [39].
Treatments targeting the amyloid pathway aim to stop
the development and progression of the disease, and hence
prevent it from developing [40–43]. Rafii [44] has argued
that disease-modifying treatments must therefore target
prodromal and pre-clinical stages of AD and be initiated
before the full symptoms of dementia appear and signifi-
cant levels of neurodegeneration become established.
Barage and Sonawane [45] reviewed the theories on the
pathogenesis of AD and the current studies on factors that
may interfere in the process. Inhibitors of cleaving
enzymes, such as BACE and c-secretase, have been pro-
posed as potential modifiers of the amyloid cascade and,
consequently, the b-amyloid deposition in the brain.
Below, we briefly review four approaches that target
pathways that may influence the extent of amyloid depo-
sition and then consider the challenge of any treatment
trial.
BACE inhibitors
b-Secretases (BACEs) cleave APP at its b-site, producing
Aß after an additional cleavage by c-secretase. Mutations
in APP that occur close to this b-site are known to be
triggers for the production of Ab and some toxic species of
Ab, including Ab42, leading to an early onset dementia
[46]. BACE1 has been found to be up-regulated in trisomy
21 cells, resulting in an increased production of Ab [47].
Inhibiting BACE1 could, therefore, be a potential thera-
peutic target for AD in DS. The gene for BACE2, a
homologue of BACE1, which is located on chromosome
21, however, has no relationship in humans to APP
cleavage [48], although one in vitro study with BACE2
raised the possibility that this enzyme may have a protec-
tive effect [49]. Studies using animal models have sup-
ported the idea that b-secretase inhibitors reduce the
amount of amyloid protein in the brain, cerebrospinal fluid
(CSF), and plasma [50, 51]. A recent study using
2-aminooxazoline and 3-azaxanthenes as BACE inhibitors
in a rat model reported a significant reduction in amyloid
levels in the brain and CSF [52]. However, according to
Varghese [26] there are still no inhibitors that have been
found to lower Ab in the brain or CSF in humans.
c-Secretase modulators
The c-Secretase enzyme is the catalyst for the last stage of
cleavage of b-amyloid precursor protein leading to the
release of the Ab peptide [53]. In 1999 De Strooper and
Konig initiated a Phase I clinical trial of a c-secretase
inhibitor [54]. The trial ended because of toxicity but since
then there have continued to be attempts to develop suit-
able modulators for this enzyme [55–58]. With some suc-
cess Netzer et al. [51] used a c-secretase (DAPT) inhibitor
in a DS mouse model to lower amyloid levels and correct
learning deficits. A protein that interacts with this enzyme
and is part of the amyloidogenic pathway, the c-secretase
activating protein (GSAP), has also been studied in people
with DS, and has been found to facilitate b-amyloid pro-
duction without having a toxic effect, so its inhibition
could be a target for development [59].
Anti-inflammatory drugs
Because the deposits of amyloid protein and the neurofib-
rillary tangles activate an inflammatory response in the
brain [60], which leads to an exacerbation of the patho-
genesis of AD [61], several clinical trials using non-ster-
oidal anti-inflammatory drugs (NSAIDs) are currently
being undertaken [61–63]. This group of anti-inflammatory
agents has been shown to prevent human Ab aggregation
in vitro [64]. However, a study that looked at the effects of
the drugs Rofecoxib and Naproxen in participants with
mild to moderate AD reported that they did not reduce
cognitive decline [65]. Using mouse models of DS, Cuello
et al. [66] reported that the anti-inflammatory agent,
minocycline, improved behavioural problems and reduced
early inflammatory factors and Ab protein in the brain,
suggesting that this approach could be a therapeutic
strategy.
J Neurol
123
Immunotherapy
Immunotherapy is also under investigation using different
approaches, such as vaccines against synthetic Ab42, frag-
ments of Ab protein conjugated to proteins, and also passive
immunisation with antibodies [67]. In 1999 Schenk et al.
succeeded in preventing the formation of Ab plaques by
immunising young transgenic AD mice that over-expressed
APP, suggesting the possibility that this immunisation could
also be used in humans to prevent AD [68]. The clinical trial
that followed this discovery had to be stopped when 6 % of
its participants developed a sub-acute meningoencephalitis
related to the Ab42 immunisation [69]. However, subse-
quent analysis of the trial showed that the 30 participants who
had developed Ab42 antibodies progressed at a slower rate
[70]. Currently, there are three peptides in phase 2 clinical
trials [71–73]. In the context of DS, these vaccines have been
used in mouse models and have been shown to improve
cognitive deficits, and also to prevent cholinergic neuronal
atrophy without obvious side effects [74]. In terms of passive
immunotherapy, there are four antibodies—solanezumab,
gantenerumab, crenezumab, and aducanumab—that are
currently in phase 2 or 3 clinical trials for AD investigating
effects on outcomes including amyloid binding and on dif-
ferent biomarkers [75–81].
Thus, for people with DS in which excess Ab production
leads in part to AD, therapies aimed at the amyloid path-
ways to reduce production, increase elimination, or modi-
fying its effects are available. However, to date, no such
trials have been done in patients with DS.
Biomarkers as proxy outcome measures of AD in DS
Figure 2 summarises the proposed time course of neu-
ropathological and clinical changes across age in people
with DS (based on the model by Jack and Holtzman [82]).
There is a 20-year or longer period of time between the first
neuropathological abnormalities and the development of
AD symptoms, which means that measures other than
clinical ones are needed for the trial of preventive
therapies.
The Down Syndrome Biomarker Initiative (DSBI)
reported by Rafii et al. [83] has investigated different types
of biomarkers, including: retinal amyloid imaging, PET
neuroimaging, and blood markers, and their relationship to
neuropsychological findings in people with DS. We con-
sider some of these below.
Plasma biomarkers
Increased levels of plasma Ab42, thought to be the toxic
species of APP, has been associated with mutations in the
APP and presenilin genes, which themselves are associated
with early onset of AD [84] and have been found to be
correlated with cognitive decline [85]. In 2001 Schupf et al.
reported that there was a sixfold increase of Ab in the
plasma of adults with DS, compared to age-matched people
without DS. Both species of the b-amyloid protein (Ab42
and Ab40) appeared to be significantly higher in the
plasma of individuals with DS, and levels may relate to the
stage of the progression of the disease [86]. A decline in
levels of Ab42 and in the Ab42/Ab40 ratio with an
increase in Ab40 in people with DS could be indicators of
AD [87]. Recently, Coppus et al. [88] published another
study on plasma b-amyloid biomarkers, and observed a
strong relationship between high plasma concentration of
Ab42 and Ab40 and the risk of dementia in individuals
with DS, suggesting the possibility of using them as pre-
dictors for dementia.
Cerebrospinal fluid (CSF) biomarkers
Different kinds of CSF biomarkers have also been studied
for more than a decade in individuals with AD, the most
frequent being biomarkers for amyloid and tau pathology
[89–91]. In a recent study in the general population, it was
observed that levels of Ab42 in CSF decrease at least
5–10 years before someone with Mild Cognitive Impair-
ment (MCI) converts to AD, while other molecules like
T-tau and P-tau appear to be later markers of the disease
[92]. Fortea et al. [93] studied CSF biomarkers in people
with DS with dementia compared to those without. The
preliminary results of this study showed that most people
with DS over 30 years of age had at least one altered
biomarker, normally Ab in CSF, independent of their
clinical diagnosis. CSF Ab levels are high in children with
DS but decrease in later life, and in a study of 12 people
with DS with a mean age of 41 years, levels of Ab1-42
Fig. 2 Hypothetical model for development of dementia in people
with Down’s syndrome [81]
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were reduced compared to aged matched controls, as were
other endogenous peptides. In contrast, Ab1-28 levels were
increased in those with DS [94].
Neuroimaging investigations (PET ligand-based, MRI,
and FDG-PET neuroimaging)
Neuroimaging techniques, such as magnetic resonance
imaging (MRI) and positron emission tomography (PET),
are clearly important tools for identifying the abnormalities
that AD causes in the brain. In 2005, Teipel and Hampel,
using high-resolution MRI to measure atrophy in different
regions of the brain of participants with DS, reported that
age-related cerebral atrophy in people with DS happened
before the onset of clinical signs of the disease [95]. A
different MRI study looking at DS participants, with and
without AD, found evidence that individuals with AD had
significantly smaller medial temporal and striatal regions
than those without AD, and thus could represent potential
cerebral markers of dementia [96]. The same researchers a
year later (2010), using MRI neuroimaging, reported
accelerated atrophy in some regions of the DS brain, which
was associated with an increased risk of dementia [97].
Different tracer compounds for the in vivo imaging of
brain amyloid, neurofibrillary tangles, and activated
microglia have been developed for use in PET scans [91].
One group recently evidenced a significant relationship
between age and higher levels of amyloid deposition (PiB
retention) in neocortical regions in asymptomatic partici-
pants with DS [98]. However, they also found no signifi-
cant differences between positive PiB binding on such a
scan and lower scores in neuropsychological tests, sug-
gesting that DS adults have a tolerance for the deposition of
Ab. Amyloid binding was also first observed in the stria-
tum in people with DS, a region also commonly affected in
sporadic early onset AD [99]. In the case of DS this was
observed around the age of 40, and was associated with
dementia and cognitive decline [100].
Another study with a group of DS participants at risk of
dementia was undertaken using FDG-PET [101]. This study
showed a correlation between a higher glucose rate in
middle-aged DS adults without AD and a lower rate in some
regions of the brain when dementia is present. Research
using Florbetapir-PET for amyloid binding, together with
other imaging techniques, found an association between DS
individuals with dementia and an increased fibrillar b-
amyloid deposition, a lower cerebral metabolic rate for
glucose, and reduced grey matter volume, in comparison
with healthy controls and people with DS without dementia.
This method could potentially be used to track neu-
ropathological changes in pre-clinical stages of AD in
adults with DS [102], but these changes do occur relatively
late with respect to the onset of neuropathology.
Electroencephalography (EEG)
Compared to other possible biomarkers, neurophysiologi-
cal measures, such as EEG, have received less attention,
especially in the DS population. A meta-analysis that
summarised the diagnostic accuracy of EEG diagnosis in
dementia concluded that the EEG was not a sufficiently
reliable tool for use in clinical practice for the diagnosis of
MCI [103]. However, Jackson and Snyder [104] analysed
the applicability of quantitative EEG as a marker of pro-
dromal impairment and the progression of the disease,
reporting that such changes were a reliable and sensitive
biomarker of MCI and AD. In respect to research in DS, in
1993 one study used quantitative EEG to investigate the
relationship between such measures and neuropsychologi-
cal performance. They compared findings between the DS
participants and people with probable AD [105], conclud-
ing that studies with people with DS of different ages could
enable the development of a model of the progression of
AD. Another article reported that in people with DS a
reduction in the dominant occipital rhythm was related to
AD and that the frequency of the same region’s activity
decreased at the onset of cognitive deterioration [106]. In
2015 Salem et al., using quantitative EEG, noticed a sig-
nificant decrease in the centroid frequency in people with
DS and AD compared to those without any cognitive
decline [107]. The conclusion of the study suggested that
EEG might serve as a potential diagnostic tool, for
enabling the prediction of AD, although they also empha-
sised the need for more studies.
Detectable changes in the eye
As the optic nerve and retinal nerve fibres have similar
embryological origins as the central nervous system,
studies have been published relating AD to abnormalities
in these structures. Using a linear discriminant function
(LDF) for multiple retinal measurements taken using a
Fourier domain optical coherence tomography (OCT), it
was found that the LDF was a better predictor of AD than
any single measurement [108]. Other studies have reported
a reduction in the thickness of the parapapillary and mac-
ular retinal nerve fiber layer (RNFL) and in macular vol-
ume, measured using OCT, in patients with AD and also a
relationship between the loss of macular volume and the
severity of AD [109]. Using this same instrument, different
studies have also reported similar reductions in the RNFL
thickness [110, 111] at different stages of the disease. Such
a relatively non-invasive technique might therefore con-
tribute towards an early diagnosis of AD [112, 113]. A
study in people with DS using similar techniques is in
progress. Investigation of the lenses in individuals with DS
revealed the accumulation of Ab aggregates, characterising
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the beginning of a cataract forming process [114] similar to
that which has been seen in the lenses of people with AD
without DS [115]. The pilot study from the Down Syn-
drome Biomarker Initiative (DSBI) observed amyloid
plaques on retinal imaging, using a Neurovision retina high
density scan, but found no correlations between retinal
amyloid and cognitive deficits [83].
Discussion
People with DS are at high risk of developing Alzheimer’s
dementia relatively early in life. The most likely explana-
tion for this risk is the ‘amyloid cascade hypothesis’. Thus,
people with DS are an ideal group for investigating AD and
also likely to benefit from new treatments that are devel-
oped for this condition. However, most of the medications
available at the moment are symptomatic. The BACE
inhibitors, 2-aminooxazoline and 3-azaxanthene, and c-
secretase modulators, DAPT, have been proven to reduce
Ab in mouse models but are still being trialled in humans
with AD. Active Ab42 immunotherapy tested in mouse
models of DS has shown improvements in cognitive
function and reduction in neuronal atrophy, without obvi-
ous side effects. At the same time, different methods of
passive immunotherapy are currently in Phase 2/3 clinical
trials for AD. Anti-inflammatory drugs (NSAIDs) were
recently reported in a published meta-analysis as being
ineffective in AD, even though their use in mice models of
DS proved to be beneficial in reducing cerebral Ab protein
deposition.
The identification of early biomarkers for AD in people
with DS is important as such proxy markers for the disease
process will be necessary if preventative, as opposed to
symptomatic, treatments are ultimately to be evaluated
over an acceptable time scale. However, despite advances
in this area evidence is needed that existing biomarkers
have sufficient sensitivity and specificity to predict the
development of AD in DS. Plasma and CSF markers (Ab
species), along with eye changes, still require further
research. MRI and PET approaches have shown some
promise, but the disease process is already advanced when
such changes are easily seen using these techniques.
Finally, studies using EEG have suggested that it might be
a potential tool for the early detection and monitoring of
the pre-symptomatic and subsequent course of AD in DS.
Since the pathological changes of AD are present before
the onset of symptoms in people with DS, research on
treatments for this disease need to focus on triggers and
steps in the amyloid pathway, reducing the production or
enhancing the clearance of Ab protein in the brain and,
consequently, arresting or delaying the development of the
disease, assuming that it is correct that it is excess amyloid
and the subsequent cascade of neuropathological events
that are driving this process. Also it is crucial to identify
biomarkers for AD in this population so as to be able to
determine the efficacy of any new treatments early in the
course of the underlying disease process and well before
the AD-related pathology and cerebral atrophy have
become established.
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Appendix
Appendix: PRISMA flowchart of methodology [116].
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